-
Gilead Sciences appoints Peter Wickersham to vice-president and general manager in the UK and Ireland
08 May 2024 12:05 GMT
Gilead Sciences has announced the appointment … all of Gilead’s portfolio of innovative products.
With more than 25 … Josephine Comiskey, senior vice-president, Gilead Sciences, Australia-Canada-Europe said: “Under … role of president of Gilead Sciences France.
-
Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead Sciences, Astellas Pharma
06 May 2024 17:00 GMT
… Disease Therapeutics Market Company and Product Profiles
9
Project Approach
10 … , Gilead Sciences, ENYO Pharma, Histogen, among others. Non-Alcoholic Fatty Liver Disease Pipeline …
-
Cut or Keep Running? How Companies Respond to Failed Confirmatory Trials
13 May 2024 05:15 GMT
… year.
Market withdrawal and pipeline decisions after late-stage failures … increased risk of death. Gilead Sciences’ Zydelig for lymphoma and … with Relyvrio its only marketed product.
If a company is … cash” with no alternative products, a failed trial “might …
-
Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024
07 May 2024 12:38 GMT
… Highlights Progress in Gastrointestinal Pipeline
An updated analysis from … lung and colorectal cancers.
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical … clinical trial supply and commercial product manufacturing.
Forward-Looking Statements …
-
Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript
30 Apr 2024 16:32 GMT
… reflected the diversity of our portfolio. HIV product sales grew 4% year … progress our industry-leading virology pipeline, which is building momentum following … ;A Session Follow Gilead Sciences Inc. (NASDAQ:GILD) Follow Gilead Sciences Inc. (NASDAQ:GILD …
-
Gilead Sciences (GILD) Q1 2024 Earnings Call Transcript
26 Apr 2024 03:40 GMT
… Image source: The Motley Fool.
Gilead Sciences (GILD -2.70%)
Q1 … the diversity of our portfolio. HIV product sales grew 4% year … our industry-leading Virology pipeline, which is building momentum … rest of our Inflammation pipeline, we have several early …
-
Gilead Sciences Announces First Quarter 2024 Financial Results
25 Apr 2024 20:12 GMT
… ’s HIV long-acting treatment pipeline. For once-weekly oral dosing … ”) to Gilead’s Liver Disease portfolio. Seladelpar is an investigational, oral … -GAAP Financial Information section above.
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
Three …
-
ClearBridge All Cap Value Strategy Q1 2024 Portfolio Manager Commentary
27 Apr 2024 21:11 GMT
… 2024. Source: ClearBridge Investments Portfolio Performance Long-term expectations for … Producers have already significantly cut production, while mounting demand growth … returns were QuidelOrtho (QDEL), APA, Gilead Sciences (GILD), UnitedHealth and Biogen ( …
-
Nurix Therapeutics announces extension of research collaboration with Gilead Sciences
03 Apr 2024 11:07 GMT
… inflammatory diseases, announced that Gilead Sciences has elected to extend the … a testament to the productivity of our collaboration to … candidates to advance a portfolio of novel targeted protein … as royalties on future products.
Nurix Therapeutics is a …
-
Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences
02 Apr 2024 11:00 GMT
… candidates to advance a portfolio of novel targeted … as royalties on future products. About Nurix Therapeutics, … owned, clinical stage pipeline includes targeted protein degraders … Nurix’s collaboration with Gilead Sciences, including the potential …